Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling-Reference-Cited by-同舟云学术

Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling

Published:2023-01-03 Issue:1 Volume:133 Page:
ISSN:1558-8238
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Ding Ling,Chen Xi,Zhang Wenxin,Dai Xiaoyang,Guo Hongjie,Pan Xiaohui,Xu Yanjun,Feng Jianguo,Yuan Meng,Gao Xiaomeng,Wang Jian,Xu Xiaqing,Li Sicheng,Wu Honghai,Cao Ji,He Qiaojun,Yang Bo

Funder

National Natural Science Foundation of China

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/154754/files/pdf

Reference52 articles.

1. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

2. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

3. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

4. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade

5. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineering PD-L1 targeted liposomal canagliflozin achieves multimodal synergistic cancer therapy;Chemical Engineering Journal;2024-10

2. Zosuquidar Promotes Antitumor Immunity by Inducing Autophagic Degradation of PD‐L1;Advanced Science;2024-09-04

3. New horizons in the mechanisms and therapeutic strategies for PD-L1 protein degradation in cancer;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

4. Ubiquitin modification in the regulation of tumor immunotherapy resistance mechanisms and potential therapeutic targets;Experimental Hematology & Oncology;2024-08-30

5. Humanized Mouse Models of Bacterial Infections;Antibiotics;2024-07-11